| Alexandra Jean Bunch, | |
|
2325 Clement Ave Ste A, Alameda, CA 94501-7061 | |
| (510) 629-6300 | |
| Not Available |
| Full Name | Alexandra Jean Bunch |
|---|---|
| Gender | Female |
| Speciality | Student In An Organized Health Care Education/training Program |
| Location | 2325 Clement Ave Ste A, Alameda, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316621360 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Secondary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Alexandra Jean Bunch, 2325 Clement Ave Ste A, Alameda, CA 94501-7061 Ph: () - | Alexandra Jean Bunch, 2325 Clement Ave Ste A, Alameda, CA 94501-7061 Ph: (510) 629-6300 |
News Archive
If there is a silver lining to the flawed U.S. response to the coronavirus pandemic, it is this: The relatively high number of new cases being diagnosed daily — upward of 20,000 — will make it easier to test new vaccines.
Veterans of Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) frequently experience high rates of PTSD along with symptoms of depression and pain. However, little is known about why these symptoms occur together or the most effective treatments that can be used to alleviate them. One approach that may yield new insights is to search for biomarkers - indicators of a biological state that can be easily and reliably measured in people with an illness - to see if their presence or absence can predict symptoms that an individual will experience and identify optimal treatment strategies.
Van Andel Research Institute (VARI) scientists have determined how two proteins required for the initiation and development of prostate cancer interact at the molecular level, which could lead to improved treatments for the disease.
A non-invasive diagnostic tool to detect surface cancers quickly and painlessly using technology currently employed by gyms to calculate body composition has been developed by a QUT PhD medical physics researcher.
Aradigm Corporation announced the last patient was enrolled in a Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (CFI, ARD-3100) in patients with non-cystic fibrosis bronchiectasis (BE), a severe progressive respiratory disease for which there is currently no approved treatment in the U.S.
› Verified 3 days ago